"Johnson  Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a latestage trial.  Two doses of Stelara already approved for psoriasis psoriatic arthritis and Crohns disease was tested in  patients with moderatetosevere ulcerative colitis UC who had failed prior therapy.  Both  mgkg and  mg doses of the intravenous treatment showed clinical remission in significantly more patients compared with those on placebo after eight weeks the company said.  The treatment and the placebo arms reported similar proportion of side effects with one patient on the  mgkg dose dying following excessive bleeding JJ said.  Sponsored The patient had no prior history of high blood pressure or cirrhosis the drugmaker said.  More than half of UC patients have not experienced remission with currently available treatment options the studys lead investigator Bruce Sands said.  Stelara which brought in sales of . billion in the second quarter of  is also being tested in autoimmune disease lupus.  Ulcerative colitis which affects about  people in the United States annually is a chronic condition causing abdominal pain intestinal ulcers bloody diarrhea and weight loss.  Current treatments include Pfizer Incs Xelijanz an oral treatment for adults patients with moderatetosevere UC and Merck  Cos Renflexis.  This story has been refilled to correct the dosage to  mg not  mgkg in paragraph   Reporting by Manogna Maddipatla in Bengaluru Editing by Sriraj Kalluvila Our StandardsThe Thomson Reuters Trust Principles. httpthomsonreuters.comenaboutustrustprinciples.html"